Page 46 - ESGO - Vulvar cancer - Complete report_fxd2

Table 14. Original studies presenting response and survival data in recurrent patients treated with chem

Authorreference Year Chemotherapy regimen Radiotherapy regimen

Scheistroen et al.251 1993 22 Bleo 30 mg IV d1, 3, 5 during weeks 1 + 3 of 30-45 Gy in 3 Gy daily fraction
radiotherapy

Landoni et al.a,244 1996 17 5-FU 750 mg/m² infusion d1-5 + MMC 15 54 Gy in 2 courses (36 Gy
mg/m² IV d1 given week 1 of each course of Gy) with 14 d treatment break
radiotherapy

Sebag-Montefiore et al.227 1994 16 5-FU 750 mg/m² infusion d1–5 + MMC 10 45 Gy in 2-2.5 Gy daily fractio
mg/m2 IV d1, given first 5 d and last 5 d of
radiotherapy

Thomas et al.230 1989 15 5-FU 1,000 mg/m² infusion d1-4 ± MMC 6 40-64 Gy in 1.6-1.8 Gy twice
mg/m² (4/6 one injection, and 2/6 two fractions

injections 4 weeks apart)

Tans et al.228 2011 8 5-FU 1,000 mg/m² infusion d1-4 + MMC 10 Split course 40 Gy + 20 Gy in
mg/m² IV d1, given first week of each course fractions with 2-week break
of radiotherpay

Russel et al.229 1992 7 5-FU 750-1,000 mg/m² infusion d1-4 + CisP 54 Gy for macro and 36 Gy

100 mg/m² IV d1, 2-3 cycles given microscopic disease

Lupi et al.a,252 1996 7 5-FU 750 mg/m² infusion d1-5 + MMC 15 54 Gy in 2 courses with 1

mg/m² IV d1, given for 2 cycles treatment break

Kalra et al.a,241 1985 1 MMC 10 mg/m² IV d1 + 5-FU 1000mg/m² 50 Gy in 2 Gy daily fractions
infusion d1-5, given weeks 1 and 4 of
radiotherapy

a Radiotherapy given to the vulva, groin and pelvis unless otherwise stated, 5-FU: 5-fluorouracil, Bleo: bleomycin, CR: comp
not available, NED: no evidence of disease and no recurrence, pCR: pathologic complete response, pPR pathologic partial res

 VULVAR CANCE
46